Difference between revisions of "Team:Fudan/Applied Design"

Line 42: Line 42:
 
<h></h>
 
<h></h>
 
   <h class="highlight-title dark-blue"></br></br>Target antigen density heterogeneity</h>
 
   <h class="highlight-title dark-blue"></br></br>Target antigen density heterogeneity</h>
−
   <p></br>The expression of the antigen on individual cells within a given tumor is different or heterogeneous. A solid tumor mass consists of numerous tumor cells. In thesetumor cells, some may express relatively less tumor antigens, others may express relatively more tumor antigens. Meanwhile, a given tumor antigen is not only expressed on malignant cells, but may also be expressed on normalcells at a low level <font color="#004a84">(Figure 1A)</font>. Thus, normal cells expressing low level of tumor antigens subsequently should not be targeted, otherwise would casusecomplications. Carefully control the on-target/off-tumor effect is critical for the success of immunotherapy. <font color="#004a84">(Figure 1B)</font> </br></br>
+
   <p></br>The expression of the antigen on individual cells within a given tumor is different or heterogeneous. A solid tumor mass consists of numerous tumor cells. In these tumor cells, some may express relatively less tumor antigens, others may express relatively more tumor antigens. Meanwhile, a given tumor antigen is not only expressed on malignant cells, but may also be expressed on normal cells at a low level <font color="#004a84">(Figure 1A)</font>. Thus, normal cells expressing low level of tumor antigens subsequently should not be targeted, otherwise would casuse complications. Carefully control the on-target/off-tumor effect is critical for the success of immunotherapy. <font color="#004a84">(Figure 1B)</font> </br></br>
 
</p>
 
</p>
 
</div>
 
</div>
−
 
+
<div>
 +
<center><img width="50%" src="https://static.igem.org/mediawiki/2017/c/c0/T--Fudan--Figure1A.png"></center>
 +
</div>
 
<div class="block main-text main-text">
 
<div class="block main-text main-text">
 
   <h class="highlight-title dark-blue"></br></br>Limitedtreatment cannot suit all cases</h>
 
   <h class="highlight-title dark-blue"></br></br>Limitedtreatment cannot suit all cases</h>
−
   <p></br>Carcinogenesis is a gradual progress driven by the accumulation of mutations. Tumor cells are highly heterogeneous in their surface tumor antigen expression<sup>(1)</sup>, thusimmune resistance<sup>(2)</sup>, sensitivity to the treatment and so on. Meanwhile, efficient recognition by immunotherapy, as one of the fundamental challenges for solid tumors, is still in the way comparing with exciting results shown in treating hematological cancers<sup>(3)</sup>.Currently, most existing immunotherapies exhaust in trying multiple methods to improve recognition<sup>(4-6)</sup>, withoutconsideratingtumor heterogeneity. They focus narrowly on finding an ideal tumor antigen as the target and hope to generate a effective therapeutic response – monotonic response.We believe these conventional one-size-fits-all immunotherapiescannot adapt itself to all complex diseaseoccasions in various types of tumors.<font color="#004a84">(Figure 1B)</font></br></br>
+
   <p></br>Carcinogenesis is a gradual progress driven by the accumulation of mutations. Tumor cells are highly heterogeneous in their surface tumor antigen expression<sup>(1)</sup>, thus immune resistance<sup>(2)</sup>, sensitivity to the treatment and so on. Meanwhile, efficient recognition by immunotherapy, as one of the fundamental challenges for solid tumors, is still in the way comparing with exciting results shown in treating hematological cancers<sup>(3)</sup>.Currently, most existing immunotherapies exhaust in trying multiple methods to improve recognition<sup>(4-6)</sup>, without considerating tumor heterogeneity. They focus narrowly on finding an ideal tumor antigen as the target and hope to generate a effective therapeutic response – monotonic response.We believe these conventional one-size-fits-all immunotherapies cannot adapt itself to all complex disease occasions in various types of tumors.<font color="#004a84">(Figure 1B)</font></br></br>
 
</p>
 
</p>
 
</div>
 
</div>
 +
 +
  
 
</html>
 
</html>
  
 
{{Fudan/PageFooter}}
 
{{Fudan/PageFooter}}

Revision as of 14:32, 30 October 2017



SwordS

Antigen density heterogeneity and limited treatment,
two obstacles in improving therapeutic effect and applicability of immunotherapy

Target antigen density heterogeneity


The expression of the antigen on individual cells within a given tumor is different or heterogeneous. A solid tumor mass consists of numerous tumor cells. In these tumor cells, some may express relatively less tumor antigens, others may express relatively more tumor antigens. Meanwhile, a given tumor antigen is not only expressed on malignant cells, but may also be expressed on normal cells at a low level (Figure 1A). Thus, normal cells expressing low level of tumor antigens subsequently should not be targeted, otherwise would casuse complications. Carefully control the on-target/off-tumor effect is critical for the success of immunotherapy. (Figure 1B)



Limitedtreatment cannot suit all cases


Carcinogenesis is a gradual progress driven by the accumulation of mutations. Tumor cells are highly heterogeneous in their surface tumor antigen expression(1), thus immune resistance(2), sensitivity to the treatment and so on. Meanwhile, efficient recognition by immunotherapy, as one of the fundamental challenges for solid tumors, is still in the way comparing with exciting results shown in treating hematological cancers(3).Currently, most existing immunotherapies exhaust in trying multiple methods to improve recognition(4-6), without considerating tumor heterogeneity. They focus narrowly on finding an ideal tumor antigen as the target and hope to generate a effective therapeutic response – monotonic response.We believe these conventional one-size-fits-all immunotherapies cannot adapt itself to all complex disease occasions in various types of tumors.(Figure 1B)